Probiotic expressed multi-target nanobody polymeric linker capable of treating cancers

Abstract

The invention relates to a probiotic expressed multi-target nanobody (Nb or VHH) polymeric linker which is formed by connecting specific VHH monomer nanobodies aiming at target spots HER2 (Human Epidermal Receptor 2), EGFR (Epidermal Growth Factor Receptor) and VEGF (Vascular Endothelial Growth Factor) through polypeptide chain connection Linker, and DNA (Deoxyribonucleic Acid) of the multi-target nanobody polymeric linker is transferred and loaded into oral probiotics. Strains of the oral probiotics can live in a gastrointestinal system of a human body for certain time, and a polymeric linked multi-target nanobody is expressed and released to treat gastric cancer. The nanobody polymeric linker provided by the invention exerts the advantages of small size of the nanobody, high stability, acid and alkali environment resistance and capability of penetrating through human body tissues; the defect that the half-life period of the nanobody in the human body is short is overcome; and a new way for treating the gastric cancer through orally taking antibody medicines is created. The nanobody polymeric linker provided by the invention exerts a multi-target cancer cell growth inhibiting effect, and the anti-cancer effect is enhanced by dozens of times even hundreds of times when being compared with the effect of simple random mixing of monomer antibodies.

Description

technical field [0001] The invention relates to a nanobody polymer link body, which uses food-grade probiotics to express the nano antibody polymer link body to target gastric cancer tumor targets to treat gastric cancer. Background technique [0002] Gastric cancer is one of the common malignant tumors of the digestive system, and most patients are already at an advanced stage when diagnosed. Worldwide, gastric cancer is the second leading cause of cancer deaths every year. The annual death rate of gastric cancer per 100,000 population in my country is 25.21%, ranking first among various malignant tumors. Chemotherapy is still the main treatment for advanced gastric cancer, but the curative effect of chemotherapy is not satisfactory. Local recurrence and distant metastasis are the main reasons affecting the 5-year survival rate after surgery. The current level of chemotherapy has reached a bottleneck, the best response rate is less than 50%, and the median overall surviva...

AI Technical Summary

Problems solved by technology

Chemotherapy is still the main treatment for advanced gastric cancer, but the curative effect of chemotherapy is not satisfactory. Local recurrence and distant metastasis are the main reasons affecting the 5-year survival rate after surgery

The current level of chemotherapy has reached a bottleneck, the best response rate is less than 50%, and the median overall survival rarely exceeds 12 months. If you want to make a breakthrough, biological therapy has become a necessary choice

[0008] In recent years, molecular targeted therapy drugs have achieved some results in the treatment of gastric cancer, but due to the relatively complicated preparation and high price, the scope of application has been limited to a certain extent

Images